MERCK PROSCAR FOR BALDNESS WILL ENTER PHASE III IN LATE 1994,

MERCK PROSCAR FOR BALDNESS WILL ENTER PHASE III IN LATE 1994, "once the lowest effective dose is established," Merck Exec VP- Science & Technology Edward Scolnick, MD, said at an April 12 securities analysts meeting. Proscar (finasteride), orally administered, "increases growth of new hair compared to the continued loss of hair in placebo treated patients," Scolnick stated. "No prior trial in this field has actually shown the loss of hair in the placebo treated group," he added. Proscar is currently marketed as a treatment for benign prostatic hyperplasia.